iiinova — where your digital self keeps evolving

Mathieu Choufani @mchoufani.bsky.social · 01/04/2025

4/ Diversity in axSpA drug trials is improving, but we still have a long way to go. Greater inclusion by race, ethnicity, gender, and geography is important to ensure trial findings are more applicable to the patients we see in our clinics.

020 2

Mathieu Choufani @mchoufani.bsky.social · 01/04/2025

3/ - 53 countries enrolled patients; but many regions had minimal participation in trials including Sub-Saharan Africa, South/Central Asia, Latin America and the MENA. - 92% of trials conducted in high-income countries - Only 2 trials conducted in low or low-middle income countries.

110 1

Mathieu Choufani @mchoufani.bsky.social · 01/04/2025

2/ - Black patients made up just 1% of trial participants. - Only 1 Native Hawaiian/Pacific Islander ever recruited in an AxSpA drug trial! - Representation of Asian, American Indian/Alaska Native, and Hispanic/Latino participants improved (progress, but not enough).

100 1

Mathieu Choufani @mchoufani.bsky.social · 01/04/2025

1/ Key findings from our axSpA trial diversity study: - Female enrollment largely reflects disease prevalence (25% in AS, 48% in nr-axSpA) - Trials reporting participant race rose from 9% (early 2000s) to 100% (~2020). - Participant ethnicity reporting still lagging behind

100 1